Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization
{{output}}
Introduction: Up to 50% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or are refractory to first-line therapy. Tisagenlecleucel, a CD19-directed chimeric antigen receptor (CAR)-T cell therapy, is approved for pat... ...
